miR-491 was demonstrated to be a potential target for the therapy of HCCs, since it can decrease cancer stem cells-like properties of HCC by inhibition of GIT-1/NF-κB-mediated EMT (22). The gene discussed is NFKB1; the disease is hepatocellular carcinoma.